Drugs / TAK-500
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05070247 | Apr 2022 → Jan 2025 | breast cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma +6 | Takeda | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05070247 ↗ |
| Action | Activate | “a Novel Stimulator of Interferon Genes Agonist” NCT05070247 ↗ |
| Route | Intravenous | “TAK-500 IV infusion.” NCT05070247 ↗ |